Eli Lilly to spend $2.8 billion on AtaiBeckley acquisition as it ramps up Alzheimer’s prevention push
read at Endpoints ↗DealPositive
Eli Lilly is signaling a renewed focus on neuroscience, emphasizing its ambition to tackle brain disorders.
The company announced it will pay $2.8 billion upfront to acquire AtaiBeckley, a move intended to broaden its pipeline in neuropsychology.
The acquisition is positioned as a key step in Lilly's strategy to advance Alzheimer’s prevention and address broader challenges in brain health.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Q&A: Lilly returns to neuropsych and looks ahead to Alzheimer's prevention”
read at Endpoints ↗90 words · retrieved Jul 22
comments(0)
5-min edit window · permanent after that